Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts at Tertiary Care Hospital in Karachi.

Role of Intralesional Combined Injection of Furosemide and Digoxin in Cutaneous Warts.

Status

Enrolling by invitation

Phases

Early Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT06821594

Enrollment

Registered

2025-02-12

Start date

2025-04-01

Completion date

2025-09-30

Last updated

2025-02-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Cutaneous Warts

Keywords

Cutaneous warts, furosemide, digoxin

Brief summary

Identify the effects of combined intralesional furosemide 20mg/2ml and digoxin 0.5mg/2ml in cutaneous warts given weekly are rather safe and effective treatment for cutaneous warts, focusing on their effectiveness and safety, at a tertiary care hospital in Karachi, Pakistan.

Detailed description

Cutaneous warts are benign growth caused by human papilloma virus. Virus have more than 100 types of which few are responsible for cutaneous disease. Both injection furosemide and digoxin cause decrease intracellular potassium levels by interacting with cell membrane ion co-transporters (Na+/K+-ATPase and Na+-K+-2Cl-co-transporter-1) thereby causing delay in viral replication. The purpose of study is to evaluate the effects of both furosemide and digoxin given 0.2 ml once weekly for five weeks on viral warts.

Interventions

DRUGFurosemide

Furosemide 20mg/2ml and digoxin 0.5mg/2ml given 0.2 ml into the wart base once weekly for 5 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 60 Years

Healthy volunteers

Inclusion criteria

1. Patients presenting with greater than or equal to two warts 2. Either gender. 3. Age 18 - 60 years. -

Exclusion criteria

1. Pregnant or lactating women. 2. Patient not giving informed consent. 3. Patient received any treatment in the last 3 months period. 4. Patient with acute illness and immuno-suppressive disease. 5. Patient taking immuno-suppressive drugs. 6. Patient having hypersensitivity to any investigational medicine. 7. Patient having cutaneous warts on face and genitals. 8. Patient having cardiovascular disease. 9. Patient having renal disease. -

Design outcomes

Primary

Measure	Time frame	Description
Size of cutaneous wart	5 weeks	Change in the dimensions of cutaneous wart assessed by Physician's wart assessment scale weekly and through photographs taking at the start and end of the study.

Countries

Pakistan

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026